EBMT 2020 | Tocilizumab: CAR-T cell therapy in DLBCL

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, discusses the use of tocilizumab after CAR-T cell therapy for the treatment of cytokine release syndrome (CRS) in refractory diffuse large B-Cell lymphoma (DLBCL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).